| 27.65 -0.2 (-0.72%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 33.75 | 1-year : | 39.42 |
| Resists | First : | 28.89 | Second : | 33.75 |
| Pivot price | 26.72  |
|||
| Supports | First : | 25.57 |
Second : | 23.52 |
| MAs | MA(5) : | 27.85 |
MA(20) : | 26.19 |
| MA(100) : | 22.76 |
MA(250) : | 20.21 |
|
| MACD | MACD : | 1  |
Signal : | 0.9 |
| %K %D | K(14,3) : | 74.6 |
D(3) : | 80.9 |
| RSI | RSI(14): 66.2 |
|||
| 52-week | High : | 28.89 | Low : | 13.81 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ MYGN ] has closed below upper band by 27.2%. Bollinger Bands are 5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 28.3 - 28.45 | 28.45 - 28.58 |
| Low: | 26.84 - 27.03 | 27.03 - 27.19 |
| Close: | 27.36 - 27.65 | 27.65 - 27.9 |
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Fri, 26 Jul 2024
Ameritas Investment Partners Inc. Raises Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) - Defense World
Thu, 25 Jul 2024
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Tue, 23 Jul 2024
Myriad Genetics (NASDAQ:MYGN) Hits New 1-Year High at $28.00 - MarketBeat
Mon, 22 Jul 2024
Swiss National Bank Raises Stock Position in Myriad Genetics, Inc. (NASDAQ:MYGN) - Defense World
Mon, 15 Jul 2024
Myriad Genetics (MYGN) Expands in MRD Testing With New Collab - Yahoo Finance
Wed, 10 Jul 2024
Myriad Genetics (MYGN) Advances in MRD Space With New Patent - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 91 (M) |
| Shares Float | 71 (M) |
| Held by Insiders | 2.1 (%) |
| Held by Institutions | 105.7 (%) |
| Shares Short | 4,610 (K) |
| Shares Short P.Month | 4,810 (K) |
| EPS | -2.8 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.39 |
| Profit Margin | -30.3 % |
| Operating Margin | -13.9 % |
| Return on Assets (ttm) | -6.6 % |
| Return on Equity (ttm) | -29.5 % |
| Qtrly Rev. Growth | 11.6 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 8.55 |
| EBITDA (p.s.) | -0.75 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -96 (M) |
| Levered Free Cash Flow | -37 (M) |
| PE Ratio | -9.88 |
| PEG Ratio | -108.2 |
| Price to Book value | 3.29 |
| Price to Sales | 3.23 |
| Price to Cash Flow | -25.99 |
| Dividend | 1.75 |
| Forward Dividend | 0 |
| Dividend Yield | 6.3% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|